PP29 Social Preferences In Health Technology Assessments For Rare Diseases: A Systematic Literature Review Of New Analytic Approaches

Introduction Rare diseases (RD) can be severe and can dramatically reduce life expectancy and quality of life. RD therapies, mostly orphan drugs (OD), fail to meet the standard criteria for public reimbursement due to uncertainty in cost-effectiveness estimates limiting healthcare access. To address this issue, experts have suggested the integration of social preferences into health technology assessments (HTAs) by implementing different methods. Methods This systematic literature review, performed in 2021, aimed to explore worldwide experiences of social preferences integration into HTAs for RD and OD through the implementation of multiple-criteria decision analysis (MCDA), discrete choice experiments (DCE), and person trade-off (PTO), among other methods. A systematic search of the literature was conducted using PubMed, Cochrane, Embase, and Scopus databases. The PRISMA approach was used for the review phases. Finally, the Promoting Action on Research Implementation in Health Services (PARIHS) framework was used to discuss the implementation of these instruments in the RD context. Results Thirty-three articles met the inclusion criteria. The studies measured social preferences for RD and OD as part of HTA using MCDA (n=17), DCE (n=8), and PTO (n=4), among other methods (n=4). These found that patients and clinicians do not prioritize funding based on rarity. The public is willing to allocate funds only if OD demonstrates effectiveness and improves the quality of life (QoL), considering as relevant factors disease severity, unmet needs, and QoL. Conversely, HTA agency experts preferred their current approach and placed more weight on cost-effectiveness and evidence quality even though they expressed concern about the fairness of the drug review process. Conclusions MCDA, PTO, and DCE, among others, are helpful and transparent methods for assessing social preferences in HTAs for RD and OD. However, their methodological limitations, such as arbitrary criteria selection, subjective scoring methods, framing effects, weighting adaptation, and value measurement models, could be hurdles to implementation. Further research is needed to tailor these methods’ applicability and impact in different social contexts.

Authors

Publication Details

Journal
International Journal of Technology Assessment in Health Care
Published
2024-12-01
DOI
https://doi.org/10.1017/s0266462324002022
Primary Topic
Health Systems, Economic Evaluations, Quality of Life
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

PP29 Social Preferences In Health Technology Assessments For Rare Diseases: A Systematic Literature Review Of New Analytic Approaches

Lisa Hall, Gregory Merlo, Paola Vásquez
International Journal of Technology Assessment in Health Care
Health Systems, Economic Evaluations, Quality of Life
article

PP29 Social Preferences In Health Technology Assessments For Rare Diseases: A Systematic Literature Review Of New Analytic Approaches

Lisa Hall, Gregory Merlo, Paola Vásquez
article en

Abstract

Introduction Rare diseases (RD) can be severe and can dramatically reduce life expectancy and quality of life. RD therapies, mostly orphan drugs (OD), fail to meet the standard criteria for public reimbursement due to uncertainty in cost-effectiveness estimates limiting healthcare access. To address this issue, experts have suggested the integration of social preferences into health technology assessments (HTAs) by implementing different methods. Methods This systematic literature review, performed in 2021, aimed to explore worldwide experiences of social preferences integration into HTAs for RD and OD through the implementation of multiple-criteria decision analysis (MCDA), discrete choice experiments (DCE), and person trade-off (PTO), among other methods. A systematic search of the literature was conducted using PubMed, Cochrane, Embase, and Scopus databases. The PRISMA approach was used for the review phases. Finally, the Promoting Action on Research Implementation in Health Services (PARIHS) framework was used to discuss the implementation of these instruments in the RD context. Results Thirty-three articles met the inclusion criteria. The studies measured social preferences for RD and OD as part of HTA using MCDA (n=17), DCE (n=8), and PTO (n=4), among other methods (n=4). These found that patients and clinicians do not prioritize funding based on rarity. The public is willing to allocate funds only if OD demonstrates effectiveness and improves the quality of life (QoL), considering as relevant factors disease severity, unmet needs, and QoL. Conversely, HTA agency experts preferred their current approach and placed more weight on cost-effectiveness and evidence quality even though they expressed concern about the fairness of the drug review process. Conclusions MCDA, PTO, and DCE, among others, are helpful and transparent methods for assessing social preferences in HTAs for RD and OD. However, their methodological limitations, such as arbitrary criteria selection, subjective scoring methods, framing effects, weighting adaptation, and value measurement models, could be hurdles to implementation. Further research is needed to tailor these methods’ applicability and impact in different social contexts.

International Journal of Technology Assessment in Health CareVol. 40(S1)
Reduced inequalities
Openalex Percentile: Top 69%
Health Systems, Economic Evaluations, Quality of Life
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.